Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out.

This episode features insights from Vito Sperduto, Co-Head of Global M&A, Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and David Levin, Co-Head of US M&A at RBC Capital Markets.

This episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.